Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Rev Esp Patol ; 56(3): 186-190, 2023.
Artigo em Espanhol | MEDLINE | ID: mdl-37419557

RESUMO

We present a case of a 64-year-old male with a history of Crohn's disease who presented with an episode of acute abdominal pain. He was being investigated for a dermatological lesion. A skin and lung biopsy both revealed histiocytosis of the "L" (Langerhans) group. The skin biopsy showed a proliferation of histiocytic cells expressing Langerin, CD1a and S100 and the molecular study was positive for the BRAF p.V600E mutation. In the lung biopsy, a proliferation of histiocytic cells was found, which were positive for CD68 and S100 and negative for Langerin and CD1a; mutations in NRAS c.38G>A in exon 2 (p.G13D) were also detected.


Assuntos
Doença de Erdheim-Chester , Histiocitose de Células de Langerhans , Masculino , Humanos , Pessoa de Meia-Idade , Doença de Erdheim-Chester/complicações , Doença de Erdheim-Chester/genética , Doença de Erdheim-Chester/patologia , Proteínas Proto-Oncogênicas B-raf/genética , Histiocitose de Células de Langerhans/complicações , Histiocitose de Células de Langerhans/genética , Histiocitose de Células de Langerhans/patologia , Mutação , Histiócitos/patologia , Proteínas de Membrana/genética , GTP Fosfo-Hidrolases/genética
2.
Rom J Morphol Embryol ; 62(1): 309-312, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34609437

RESUMO

INTRODUCTION: Mammary analogue secretory carcinoma (MASC) is a recent discovered entity of salivary glands tumors, reported for first time in 2010. The presence of a translocation encodes the ETS variant transcription factor 6-neurotrophic tyrosine receptor kinase (ETV6-NTRK3) gene fusion differences MASC from other tumors. CASE PRESENTATION: A 68-year-old male showed a non-painful right parotid enlargement, came from dermatology service, and followed by some facial squamous cell carcinomas. A computed tomography (CT) scan showed a 1.7×1.6 cm right parotid enlargement in superficial lobe. The patient underwent a right superficial parotidectomy. The final pathology confirmed the presence of ETV6-NTRK3-positive MASC. Complete right deep parotidectomy and functional cervical emptying were performed. DISCUSSIONS AND CONCLUSIONS: It is necessary to establish an appropriated differential diagnosis between salivary gland tumors. MASC is a low-grade malignancy cancer that sometimes can evolve to a high-grade tumor that might produce local and distance dissemination. Most times, these tumors are only treated by surgical resection and evaluating by a multidisciplinary team the need of more treatments. In our case, the patient showed a primary parotid tumor, removed surgically with free edges, and being identified as MASC. We decided to underwent neck dissection and discovered a second MASC focus on cervical salivary gland; however, there was no nodal dissemination. The patient remains disease-free after 14 months from last surgery. It is important to keep studying genetic therapy targets to ETV6-NTRK3 to obtain a new therapy line to treat those cases that require.


Assuntos
Carcinoma Secretor Análogo ao Mamário , Neoplasias das Glândulas Salivares , Idoso , Biomarcadores Tumorais , Humanos , Masculino , Carcinoma Secretor Análogo ao Mamário/genética , Proteínas de Fusão Oncogênica/genética , Neoplasias das Glândulas Salivares/genética , Translocação Genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA